Effect of Remifentanil on Active Phase Duration of Labor in Nulliparous Pregnant Women: A Cross-sectional Study

Abstract

Objectives: Due to the increase in elective cesarean section and its high complications, epidural analgesia is the gold standard for reducing the pain of vaginal delivery. In contraindication cases, other effective and safe analgesic methods such as remifentanil are suggested. The present study aimed to compare the duration of active phase of labor at stages I and II, as well as neonatal Apgar score following the use of remifentanil analgesia. Materials and Methods: In this study, 120 healthy primiparous women who were candidates for vaginal delivery were selected. After matching for age and body mass index (BMI), the participants were assigned into two equal groups (n=60 each) of intervention (receiving remifentanil) and control. We compared the duration of active phase of labor at stages I and II, neonatal Apgar scores, and the cesarean section rate between the groups. Statistical analysis was performed using SPSS software (version 23). Results: There was no statistically significant difference between the two groups in terms of the duration of active phase in the first and second stages of labor (P=0.84 and P=0.78, respectively), 1-minute Apgar score (P=0.95), 5-min Apgar score (P=0.92), and the rate of cesarean section (P=0.067). Moreover, we observed no maternal complications with remifentanil. Conclusions: According to our results, remifentanil did not increase the duration of labor, rate of cesarean section, and maternal complications. Hence, it can be a good alternative in cases where epidural analgesia is contraindicated.